Dr.Reddy's Laboratories Ltd
has announced the launch of Propofol Injectable Emulsion, USP, a therapeutic equivalent generic version of Diprivan (propofol) approved by the USFDA.
"Dr.Reddy's is committed to providing affordable and innovative medicines for healthier lives. To that end, Dr. Reddy's neither condones nor supports the off-label use or misuse of its drugs," the company said in the filing.
"In the strongest possible terms, Dr.Reddy's objects to the use of any of its products to facilitate or otherwise aid lethal injections. Consistent with this position, Dr.Reddy's uses distribution controls to market Propofol Injectable Emulsion, USP," the company added.
"Dr.Reddy's will not accept orders from correctional facilities and prison systems whose intended use of the product is to aid in lethal injection. We require the same commitment from our wholesalers and distributors," the pharma company said in the filing.
The Diprivan brand and generic had sales of approximately $310 mn MAT in the twelve months to November 2018, according to IMS Health.
The drug is available in 10 mg/ml vials for single patient use only.
Dr.Reddy's Laboratories Ltd share price is currently at Rs2,657.95, up Rs12.45, or 0.47%, from its previous close of Rs2,645.50 on the BSE. The scrip opened at Rs2,640 and has touched a high and low of Rs2,670.35 and Rs2,640, respectively. So far, 4,74,969 (NSE+BSE) shares have been traded on the counter. The current market cap of the company is Rs43,931.40cr.